Gilead partners with WuXi for R&D; Isis advances a Bayer-partnered drug;

@FierceBiotech: The top 10 biopharma pipeline disasters of 2015. Feature | Follow @FierceBiotech

@JohnCFierce: Something tells me that the Pfizer/Allergan merger will inspire Ian Read to name the new company... Pfizer. | Follow @JohnCFierce

@DamianFierce: "I hope Bill Ackman has done more research on Valeant than he did on Herbalife, Target, Borders and JC Penny." Statement | Follow @DamianFierce

> Gilead Sciences ($GILD) is working with Chinese CRO WuXi PharmaTech ($WX), tasking the company with handling analytical and stability studies of investigational drugs to support global marketing applications. News

> Isis Pharmaceuticals ($ISIS) launched a Phase II study on its Bayer-partnered treatment for clotting disorders, putting it in line for a $55 million milestone payment. More

> The potential merger of Pfizer ($PFE) and Allergan ($ACT) has stirred up fresh critiques of U.S. tax policy from presidential candidates Hillary Clinton and Donald Trump. Story

Medical Device News

@FierceMedDev: Smith & Nephew to buy robotic surgical partner Blue Belt for $275M. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDrugDelivery: Flowonix to develop drug delivery implant for Cerebral's neurological candidates. Article | Follow @VarunSaxena2

@EmilyWFierce: It seemed like things couldn't get much worse for Theranos. And then, they did. More | Follow @EmilyWFierce

> Quest Medical launches recall for open heart surgery drug delivery devices. Story

> Sanofi recalls epinephrine injector devices from U.S. and Canada. Article

> Zimmer Biomet raises guidance as it squeezes out more synergies, but whence growth? More

Pharma News

@FiercePharma: Allergan pays $125M to rid itself of marketing charges tied to Warner Chilcott. Report | Follow @FiercePharma

@EricPFierce: Will Sanofi problems with auto injectors be its auto ejector from the epinephrine market? More | Follow @EricPFierce

@CarlyHFierce: "Pfallergan" - definitely the worst portmanteau I've ever seen for anything, ever. | Follow @CarlyHFierce

> Allergan pays $125M to rid itself of marketing charges tied to Warner Chilcott. Report

> Patent challenger Bass wins IP reviews for Celgene, Shire meds. Article

> Mylan beats Street's estimates with Q3 earnings and beats Perrigo in effort to derail tender. Item

Suggested Articles

The analysis found Nexvax2 was no better than placebo at protecting patients from gluten, prompting the Arch-backed biotech to stop the study.

Johns Hopkins scientists found that misfolded alpha-synuclein protein can travel from the gut and drive Parkinson's disease.

The financing sets Sanifit up to take its lead drug through phase 3 while exploring its potential in other progressive vascular calcification disorders.